Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
CA 2457461 C · Owner: Tanox, Inc. · Inventors: Lu, Meisheng; Sun, Cecily; Sun, William
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relats to inhibitors that bind to C5 and C5a but which do not , prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitors molecule is the monoclonal antibody designated MAb137-26 which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated bx excessive or uncontrolled production of C5a. The inhibitors moleculesl are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 17, 2002 and granted December 24, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.